M3DC is an independent scientific management and consulting organization specialized in:
1. the creation and management of large, multidisciplinary and cross-national research and development projects in drug discovery and drug development
2. networking with the drug development experts at the local, national and transnational community level
The individual company was founded in 2013 in Chêne-Bourg/Geneva, Switzerland, by Michel Dreano.

Previously M. Dreano served as Scientific Coordinator for a large pharmaceutical organization, Merck Serono. He had the opportunity to manage, many strategic collaborations and partnerships with academic institutions, research contract organizations, biotechs or large pharmaceutical organizations. Among others he was involved in the management of an European-funded Project. In parallel in 2013 with two ex-Merck Serono colleagues, M. Dreano incorporated a private biotech company, Relief Therapeutics SA, where he served as COO. In June 2016 Relief Therapeutics SA merged with THERAMetrics holding AG to form the publicly-traded company named, Relief Therapeutics Holding SA. Mr Dreano acted during three years as CFO. Development activities of the Group focused primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rational, especially in diseases related to diabetic complications and respiratory diseases.

Operating from Geneva, Switzerland, M3DC substantially increases the value of a project by efficiently managing its translation from the lab to clinical proof of concept with industrial applications always in sight. This responds to the current needs of many drug sponsors who tends to outsource most of their projects to contain in-house spending. M3DC is able to operate within a formal association of partners with specialised expertise in niche areas, all sharing an extensive experience in the Life Science industry.